Essential thrombocythemia is classified as a chronic myeloproliferative disorder characterized by the overproduction of platelets stemming from a megakaryocytic clone. The diagnosis primarily relies on bone marrow biopsy findings and the detection of the JAK2 V617F mutation, after the exclusion of secondary thrombocytosis due to conditions such as inflammation, hemolysis, infection, and iron deficiency. On the other hand, Ulcerative colitis represents an inflammatory disorder of the colon. The diagnosis of ulcerative colitis is established through clinical assessment, endoscopic examination, and histological criteria, without a discernible alternative etiology. The concomitant occurrence of these two conditions is infrequent. We present the case of an 85-year-old patient with a history of essential thrombocythemia who exhibited gastrointestinal symptoms characterized by alternating episodes of diarrhea and constipation. A subsequent colonoscopy accompanied by a biopsy revealed histological features consistent with ulcerative colitis. The patient was administered cytoreductive therapy in combination with mesalazine, resulting in favorable outcomes. Current literature addressing this association is limited, indicating the need for further investigative studies to elucidate the causal relationships between these two pathologies and to achieve improved therapeutic management strategies.
References
[1]
Ducloy-Bouthors, A. and Wibaut, B. (2015) Thrombocytémie Essentielle. In: Fuzier, V., Chassard, D. and Mercier, F.J., Eds., Priseenchargedesmaladiesraresenanesthésieetanalgésieobstétricales, Elsevier, 715-717. https://doi.org/10.1016/b978-2-294-74764-9.00201-6
[2]
Ungaro, R., Mehandru, S., Allen, P.B., Peyrin-Biroulet, L. and Colombel, J. (2017) Ulcerative Colitis. The Lancet, 389, 1756-1770. https://doi.org/10.1016/s0140-6736(16)32126-2
[3]
Wang, L., Yang, Y., Cheng, W., Wang, W., Lin, S. and Shieh, C. (2016) Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease: A Nationwide Population-Based Study in Taiwan Region. American Journal of Gastroenterology, 111, 1313-1319. https://doi.org/10.1038/ajg.2016.239
[4]
Askling, J. (2005) Risk of Haematopoietic Cancer in Patients with Inflammatory Bowel Disease. Gut, 54, 617-622. https://doi.org/10.1136/gut.2004.051771
[5]
Bak, M., Jess, T., Flachs, E.M., Zwisler, A., Juel, K. and Frederiksen, H. (2020) Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study. Cancers, 12, Article No. 2700. https://doi.org/10.3390/cancers12092700
[6]
Szuber, N., Mudireddy, M., Nicolosi, M., et al. (2019) 3023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data among Disease Subgroups. Mayo Clinic Proceedings, 94, 599-561.
[7]
Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., et al. (2011) Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. JournalofClinicalOncology, 29, 3179-3184. https://doi.org/10.1200/jco.2010.34.5298
[8]
James, C., Ugo, V., Le Couédic, J., Staerk, J., Delhommeau, F., Lacout, C., et al. (2005) A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythaemia Vera. Nature, 434, 1144-1148. https://doi.org/10.1038/nature03546
[9]
Besancenot, R., Pasquier, F. and Giraudier, S. (2011) Actualités 2011 sur la physiopathologie des syndromes myéloprolifératifs classiques hors LMC (polyglobulie de Vaquez, thrombocytémie essentielle et myélofibrose primaire). RevueFrancophonedesLaboratoires, 2011, 41-46. https://doi.org/10.1016/s1773-035x(11)71003-6
[10]
Medinger, M., Skoda, R., Gratwohl, A., Theocharides, A., Buser, A., Heim, D., et al. (2009) Angiogenesis and Vascular Endothelial Growth Factor‐/Receptor Expression in Myeloproliferative Neoplasms: Correlation with Clinical Parameters and JAK2-V617F Mutational Status. BritishJournalofHaematology, 146, 150-157. https://doi.org/10.1111/j.1365-2141.2009.07726.x
[11]
Neurath, M.F. (2014) Cytokines in Inflammatory Bowel Disease. NatureReviewsImmunology, 14, 329-342. https://doi.org/10.1038/nri3661
[12]
Geremia, A., Biancheri, P., Allan, P., Corazza, G.R. and Di Sabatino, A. (2014) Innate and Adaptive Immunity in Inflammatory Bowel Disease. AutoimmunityReviews, 13, 3-10. https://doi.org/10.1016/j.autrev.2013.06.004
[13]
Hermouet, S., Bigot-Corbel, E. and Gardie, B. (2015) Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. MediatorsofInflammation, 2015, Article ID: 145293. https://doi.org/10.1155/2015/145293
[14]
Geyer, H.L., Dueck, A.C., Scherber, R.M. and Mesa, R.A. (2015) Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. MediatorsofInflammation, 2015, Article ID: 284706. https://doi.org/10.1155/2015/284706
[15]
Craver, B., El Alaoui, K., Scherber, R. and Fleischman, A. (2018) The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. Cancers, 10, Article No. 104. https://doi.org/10.3390/cancers10040104
[16]
Jones, A.V. and Cross, N.C.P. (2013) Inherited Predisposition to Myeloproliferative Neoplasms. TherapeuticAdvancesinHematology, 4, 237-253. https://doi.org/10.1177/2040620713489144
[17]
Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux, J.D., et al. (2008) Genome-Wide Association Defines More than 30 Distinct Susceptibility Loci for Crohn’s Disease. NatureGenetics, 40, 955-962. https://doi.org/10.1038/ng.175
[18]
Zhang, J., Song, J., Wang, J. and Dong, W. (2014) JAK2 Rs10758669 Polymorphisms and Susceptibility to Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis. Inflammation, 37, 793-800. https://doi.org/10.1007/s10753-013-9798-5